Completed PHASE3 INTERVENTIONAL 2-arm NCT02149108

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.

Sponsor: Boehringer Ingelheim

Conditions Colorectal Neoplasms

Interventions BSC Nintedanib (BIBF 1120) Placebo

Updated 8 times since 2017 Last updated: Jun 23, 2017 Started: Sep 25, 2014 Primary completion: May 13, 2016 Completion: Aug 25, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colorectal Neoplasms, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 8 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3
Sep 2025 — Oct 2025 [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Aug 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Aug 2017 [monthly]

Completed PHASE3

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalst, Belgium , Aberdeen, United Kingdom , Adana, Turkey (Türkiye) , Aichi, Nagoya, Japan , Almada, Portugal , Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Antalya, Turkey (Türkiye) , Arlington Heights, United States and 105 more locations